Skip to main content
TipRanks
Go Ultimate75% OFF

Pharming Group (PHG) Stock Price & Analysis

0 Followers

PHG Stock Chart & Stats

€11.20-€0.20(-1.75%)
At close: 5:30 PM GMT+1
€7.5€10€12.5€15Dec 23Oct 15Feb 27Dec 29May 7Nov 3
Day’s Range
EUR 11.10 - EUR 11.20
52-Week Range
EUR 7.70 - EUR 17.40
Previous Close
EUR 11.40
Volume
N/A
Average Volume (3M)
9
Market Cap
EUR 807.58M
Enterprise Value
EUR 670.87M
Total Cash (Recent Filing)
EUR 189.56M
Total Debt (Recent Filing)
EUR 114.51M
Price to Earnings (P/E)
35.7
Beta
0.71
Next Earnings
Mar 18, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Pediatric Regulatory Expansion

The U.K. pediatric approval expands Joenja’s authorized population and strengthens Pharming’s position in targeted rare-disease treatment. Broader eligibility can support additional patient identification, international commercialization, and recurring therapy revenue over the coming quarters.

Joenja Growth And Market Expansion

Rapid Joenja growth, rising patients on paid therapy, and expansion into Germany and Japan indicate increasing commercial adoption beyond the initial U.S. market. A growing treated population and international reach can create a durable second product franchise.

Liquidity And Cash Generation

Positive operating cash flow and substantial liquidity give Pharming capacity to fund pipeline development, pediatric launches, and prelaunch costs without near-term external financing. This supports strategic flexibility while the company builds its rare-disease portfolio.

Bears Say

Unresolved CEO Transition

An unresolved leadership transition can create execution and strategic continuity risk while Pharming is commercializing Joenja and advancing multiple clinical programs. Interim leadership may also delay major decisions or reduce clarity around long-term priorities.

RUCONEST Competitive Pressure

Expected U.S. revenue contraction and the prospect of another oral competitor indicate ongoing pressure on Pharming’s largest established product. Sustaining patient retention, prescription volume, and growth may require continued commercial effort as treatment alternatives expand.

Uneven Profitability And Cash Flow

The return to positive cash generation is encouraging, but prior negative cash flow and modest operating profitability show that earnings conversion has not been consistent across the cycle. This may constrain reinvestment flexibility if product growth or margins weaken.

Pharming Group News

PHG FAQ

What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was €7.70 and its highest was €17.40 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is €807.58M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 122 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Oct 27, 2026. The company reported €0.268 earnings per share for the quarter, beating the consensus estimate of €0.187 by €0.08.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is 0.09.
How many shares outstanding does Pharming Group have?
Pharming Group has 70,778,120 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of €0.268 in its last earnings report, beating expectations of €0.187. Following the earnings report the stock price went up 0.952%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in DE:PHG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology